78 results
8-K
EX-99.1
MYMD
MyMD Pharmaceuticals Inc
5 Mar 24
Regulation FD Disclosure
11:00am
pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth
8-K
EX-99.1
MYMD
MyMD Pharmaceuticals Inc
13 Feb 24
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
4:57pm
rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion
8-K
EX-99.1
MYMD
MyMD Pharmaceuticals Inc
6 Dec 23
Regulation FD Disclosure
9:15am
pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth
8-K
EX-99.1
ytw3z
19 Oct 23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
9:00am
8-K
EX-99.1
zqbvbhqu6
4 Oct 23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4:30pm
8-K
EX-99.1
0vwr k8bb4h8b6j
14 Aug 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
08se4vu81f
31 Jul 23
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline
9:00am
8-K
EX-99.1
rbulbhm yp22
12 Apr 23
Regulation FD Disclosure
8:45am
8-K
EX-99.1
k2p58 34on
8 Dec 22
MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
4:15pm
8-K
EX-99.1
jo1q1utwx9w0ja
18 Nov 22
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
4:30pm
8-K
EX-99.1
b8341y5zcjk5wfi
14 Nov 22
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research
8:32am
8-K
EX-99.1
hrt50wys0t2dxyywg
20 Sep 22
Efficacy data anticipated in Q4 of 2022
8:00am
8-K
EX-99.1
z6un19dml t9bnqyh
31 Aug 22
Mymd Pharmaceuticals Receives Grant from European
8:00am
424B5
o8eca
17 Aug 22
Prospectus supplement for primary offering
3:00pm